Theranostics 2020; 10(21):9544-9560. doi:10.7150/thno.45788

Research Paper

Prevention of Obesity Related Diseases through Laminarin-induced targeted delivery of Bindarit

Chunmei Xu1*, Luqi Yin2*, Zhipeng Teng3*, Xuemei Zhou1, Wenjie Li1, Qiong Lai1, Cuiping Peng2, Chengyuan Zhang1,2, Jie Lou1✉, Xing Zhou1,2✉

1. School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 400054, China.
2. Department of Pharmaceutics, College of Pharmacy, Third Military Medical University, Chongqing 400038, China.
3. Department of Neurosurgery, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China.
*These authors contributed equally to this paper.

This is an open access article distributed under the terms of the Creative Commons Attribution License ( See for full terms and conditions.
Xu C, Yin L, Teng Z, Zhou X, Li W, Lai Q, Peng C, Zhang C, Lou J, Zhou X. Prevention of Obesity Related Diseases through Laminarin-induced targeted delivery of Bindarit. Theranostics 2020; 10(21):9544-9560. doi:10.7150/thno.45788. Available from

File import instruction


Rationale: The developement of oral targeted therapeutics for obesity and obesity-related diseases is challenging, as these diseases involve multiple lesions distributed throughout the whole body. Herein, we report a successful stragety for targeted oral delivery of bindarit to multiple obesity-related lesions including inflamed adipose tissue, fatty liver and atherosclerotic plaques.

Methods: The computer simulation from atomstic to mesoscale was first applied for designing bindarit-loaded nanoparticles (pBIN) and laminarin-modified bindarit-loaded nanoparticles (LApBIN). Then pBIN were suceesfully prepared using a dialysis procedure, and LApBIN were prepared though the interaction bewtween laminarin and pBIN. The physiochemical properties, in vitro and in vivo pharmacokinetics, oral targeting capability and in vivo efficacy of LApBIN in various obesity-related diseases were examined.

Results: LApBIN were sucessfully designed and prepared. Following oral administration of LApBIN, the nanoparticles could be sucessully orally adsorbed and translocated to monocytes. Contributed by the recruitment of monocytes to multiple obesity-related lesions, LApBIN successfully delivered bindarit to these lesions, and effectively suppressed inflammation there, which exerted successful preventive effects on high-fat-diet-induced obesity, insulin resistance, fatty liver and atherosclerosis.

Conclusions:This strategy could represent a promising approach to develop effective oral treatments for obesity and other metabolic diseases.

Keywords: Nanomedicines, Oral Targeted Therapeutics, Obesity, Fatty Liver, Atherosclerosis